ALPHA-TOCOPHEROL, BETA-CAROTENE LUNG CANCER PREVENTION STUDY

α-生育酚、β-胡萝卜素预防肺癌研究(ATBC 研究)正在调查每日口服α-生育酚(50)的疗效 Mg)和β-胡萝卜素(20 Mg)在双盲随机2x2因子中 旨在预防50-69岁男性肺癌的设计试验 吸烟者。该项目是基于实验和 具有潜在预防作用的流行病学研究 对这些特工来说。招募是在1985-88年间进行的，审判期间 在经过6年以上的平均随访后，将于1993年结束。A邮局 向291,000名男性发送了对潜在试验参与者的调查筛查 在芬兰南部，76%的人做出了回应。我们邀请了愿意吸烟的人 参加13个学习诊所之一(43,000人)，超过29,000人被 随机进入这项研究。每日一粒胶囊的服药依从性 一直很高(平均97%)，平均辍学率较低 每年超过6%。在活化剂中降低肺癌发病率 分组是主要的研究目标；其他组的出现差异 癌症也将被评估。几项试验性研究以支持 试验也已完成，包括可行性研究、验证 研究饮食问卷，评估皮肤变黄和 服用β-胡萝卜素后的血清水平。 这项试验是与监督中心合作进行的 计划和癌症预防和治疗部门的生物测量学分部 并与芬兰国家公共卫生研究所进行了合作。

The Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study (ATBC Study) is investigating the efficacy of daily oral alpha-tocopherol (50 mg) and beta-carotene (20 mg) in a double-blind, randomized 2x2 factorial design trial aimed at preventing lung cancer among 50-69 year old male cigarette smokers. The project is based on experimental and epidemiological research which demonstrates a potential preventive role for these agents. Recruitment took place between 1985-88, and the trial will end in 1993 after an average followup of over 6 years. A postal survey screening for potential trial participants was sent to 291,000 men in southern Finland, and 76% responded. We invited the smokers willing to participate (43,000) to one of 13 study clinics, and over 29,000 were randomized into the study. Compliance to the one capsule daily regimen has remained very high (97% average), and the dropout rate averages less than 6% per year. Reduction of lung cancer incidence in the active agent groups is the primary study goal; differences in the occurrence of other cancers will also be evaluated. Several pilot studies in support of the trial have also been completed including a feasibility study, validation of study dietary questionnaires, and evaluation of skin yellowing and serum levels following beta-carotene administration. This trial is being conducted collaboratively with the Surveillance Program and the Biometry Branch of the Division of Cancer Prevention and Control and with the National Public Health Institute of Finland.